Citi Pharma Limited (PSX: CPHL)
Pakistan
· Delayed Price · Currency is PKR 69.27
-1.91 (-2.68%)
At close: Dec 24, 2024
Citi Pharma Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2018 |
| Revenue | 12,933 | 12,409 | 12,397 | 9,780 | 5,795 | 3,528 | Upgrade
|
| Revenue Growth (YoY) | 7.95% | 0.10% | 26.76% | 68.75% | 64.29% | 35.31% | Upgrade
|
| Cost of Revenue | 11,164 | 10,823 | 10,890 | 8,417 | 5,024 | 3,100 | Upgrade
|
| Gross Profit | 1,768 | 1,586 | 1,507 | 1,363 | 771.9 | 427.59 | Upgrade
|
| Selling, General & Admin | 380.75 | 380.55 | 339.64 | 369.6 | 200.93 | 173.48 | Upgrade
|
| Operating Expenses | 380.75 | 380.55 | 339.64 | 369.6 | 200.93 | 173.48 | Upgrade
|
| Operating Income | 1,387 | 1,206 | 1,167 | 993.48 | 570.97 | 254.11 | Upgrade
|
| Interest Expense | -273.19 | -295.43 | -133.84 | -57.76 | -35.74 | -39.66 | Upgrade
|
| Interest & Investment Income | 23.77 | 23.77 | 13.54 | 20.95 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 65.52 | 65.52 | -245.68 | -6.85 | -0.64 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 210.87 | 241.28 | 175.03 | 110.75 | -34.84 | -11.92 | Upgrade
|
| EBT Excluding Unusual Items | 1,414 | 1,241 | 976.52 | 1,061 | 499.75 | 202.53 | Upgrade
|
| Gain (Loss) on Sale of Investments | 40.42 | 40.42 | -37.42 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 18.16 | - | - | - | Upgrade
|
| Pretax Income | 1,455 | 1,281 | 957.25 | 1,061 | 499.75 | 202.53 | Upgrade
|
| Income Tax Expense | 514.36 | 447.74 | 299.27 | 406.88 | 147.98 | 59.11 | Upgrade
|
| Net Income | 940.51 | 833.46 | 657.98 | 653.69 | 351.77 | 143.42 | Upgrade
|
| Net Income to Common | 940.51 | 833.46 | 657.98 | 653.69 | 351.77 | 143.42 | Upgrade
|
| Net Income Growth | 55.04% | 26.67% | 0.66% | 85.83% | 145.28% | 415.80% | Upgrade
|
| Shares Outstanding (Basic) | 228 | 228 | 228 | 227 | 106 | 99 | Upgrade
|
| Shares Outstanding (Diluted) | 228 | 228 | 228 | 227 | 186 | 99 | Upgrade
|
| Shares Change (YoY) | -0.43% | - | 0.70% | 21.65% | 88.38% | - | Upgrade
|
| EPS (Basic) | 4.12 | 3.65 | 2.88 | 2.88 | 3.31 | 1.45 | Upgrade
|
| EPS (Diluted) | 4.12 | 3.65 | 2.88 | 2.88 | 1.88 | 1.45 | Upgrade
|
| EPS Growth | 55.71% | 26.67% | 0% | 53.04% | 29.90% | 415.79% | Upgrade
|
| Free Cash Flow | 678.79 | 769.4 | -1,283 | -923.43 | -52.3 | -21.1 | Upgrade
|
| Free Cash Flow Per Share | 2.98 | 3.37 | -5.62 | -4.07 | -0.28 | -0.21 | Upgrade
|
| Dividend Per Share | 3.250 | 3.250 | 2.500 | - | 1.364 | - | Upgrade
|
| Dividend Growth | 30.00% | 30.00% | - | - | - | - | Upgrade
|
| Gross Margin | 13.67% | 12.78% | 12.16% | 13.94% | 13.32% | 12.12% | Upgrade
|
| Operating Margin | 10.73% | 9.72% | 9.42% | 10.16% | 9.85% | 7.20% | Upgrade
|
| Profit Margin | 7.27% | 6.72% | 5.31% | 6.68% | 6.07% | 4.07% | Upgrade
|
| Free Cash Flow Margin | 5.25% | 6.20% | -10.35% | -9.44% | -0.90% | -0.60% | Upgrade
|
| EBITDA | 1,532 | 1,341 | 1,258 | 1,066 | 631.68 | 303.71 | Upgrade
|
| EBITDA Margin | 11.84% | 10.81% | 10.15% | 10.90% | 10.90% | 8.61% | Upgrade
|
| D&A For EBITDA | 144.26 | 135.67 | 90.59 | 72.84 | 60.71 | 49.59 | Upgrade
|
| EBIT | 1,387 | 1,206 | 1,167 | 993.48 | 570.97 | 254.11 | Upgrade
|
| EBIT Margin | 10.73% | 9.72% | 9.42% | 10.16% | 9.85% | 7.20% | Upgrade
|
| Effective Tax Rate | 35.35% | 34.95% | 31.26% | 38.36% | 29.61% | 29.19% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.